このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

不整脈性心房細動患者を対象としたVARIPULSEカテーテルおよびTRUPULSEジェネレーターとVARIPULSE PROソフトウェアに関する研究 (VP-EXTRA)

2026年11月2日 更新者:Biosense Webster, Inc.

新しいVARIPULSE™ Proソフトウェアを用いた持続性心房細動(PsAF)治療のためのTRUPULSE™ジェネレーター搭載VARIPULSE™カテーテルのワークフロー研究

The main purpose of this study is to investigate the workflow of the clinical use of the pulsed field (PF) ablation system (VARIPULSE catheter and TRUPULSE generator) when used for cardiac ablation with the new VARIPULSE Pro software in participants with persistent atrial fibrillation (PsAF; irregular, rapid heart rhythm that lasts over 7 days and doesn't stop on its own)

調査の概要

状態

積極的、募集していない

条件

介入・治療

研究の種類

介入

入学 (実際)

42

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • San Donato Milanese、イタリア、20097
        • IRCCS Policlinico San Donato
      • Aarhus N、デンマーク、8200
        • Aarhus University Hospital
      • Bad Oeynhausen、ドイツ、32545
        • University Hospital of the Ruhr-University of Bochum
      • Aalst、ベルギー、9300
        • AZORG campus Aalst Moorselbaan
      • Bruges、ベルギー、8000
        • A.Z. Sint Jan
      • Vilnius、リトアニア、08406
        • Vilnius University Hospital Santaros Clinics

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~75年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion criteria:

  • Diagnosed with symptomatic persistent atrial fibrillation (PsAF)
  • Selected to undergo an ablation procedure for management of their arrhythmia by pulmonary vein isolation (PVI) +
  • Failed at least one antiarrhythmic drug (AAD; class I to IV) as evidenced by recurrent symptomatic atrial fibrillation (AF), or intolerable or contraindicated to the AAD
  • Age 18-75 years
  • Willing and capable of providing consent
  • Able and willing to comply with all pre-, post- and follow-up testing and requirements

Exclusion criteria:

  • Continuous AF greater than (>) 12 months (1-Year) (Longstanding Persistent AF)
  • Previous surgical or catheter ablation for atrial fibrillation
  • Any cardiac surgery within the past 2 months (60 days prior to consent date) (includes percutaneous coronary intervention [PCI])
  • Previous coronary artery bypass grafting (CABG) in conjunction with valvular surgery, cardiac surgery (for example, ventriculotomy, atriotomy) or valvular cardiac (surgical or percutaneous) procedure
  • Any carotid stenting or endarterectomy
  • Presence of left atrium (LA) thrombus
  • Severe dilatation of the LA (left atrial diameter (LAD) > 50 millimeter [mm] antero-posterior diameter in case of transthoracic echocardiography [TTE])
  • Severely compromised left ventricular ejection fraction (LVEF less than [<] 40%)
  • Known significant pulmonary vein (PV) anomaly that in the opinion of the investigator would preclude enrollment in this study
  • Prior diagnosis of pulmonary vein stenosis
  • Pre-existing hemi diaphragmatic paralysis
  • History of blood clotting, bleeding abnormalities or contraindication to anticoagulation (heparin, warfarin, or dabigatran)
  • MI within the past 2 months (60 days prior to consent date)
  • Documented thromboembolic event (including transient ischemic attack [TIA]) within the past 6 months (180 days prior to consent date)
  • Rheumatic Heart Disease
  • Uncontrolled heart failure or New York Heart Association (NYHA) function class III or IV
  • Severe mitral regurgitation
  • Anticipated cardiac transplantation, cardiac surgery, or other major surgery within the next 12 months
  • Unstable angina pectoris within the past 6 months prior to consent date
  • Acute illness or active systemic infection or sepsis
  • Previously known AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause (for example, documented obstructive sleep apnea, acute alcohol toxicity, morbid obesity (Body Mass Index >40 kilogram per meter squared [kg/m^2]), renal insufficiency (with an estimated creatinine clearance < 30 mL/min/1.73 m^2)
  • Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch, prosthetic valve or other abnormality that precludes catheter introduction or manipulation
  • Presence of intramural thrombus, tumor or other abnormality that precludes vascular access, or manipulation of the catheter
  • Presence of any other condition that precludes appropriate vascular access (such as Inferior Vena Cava [IVC] filter)
  • Significant pulmonary disease, (for example, restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease [COPD]) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms
  • Significant congenital anomaly or medical problems that in the opinion of the investigator would preclude enrollment in this study
  • Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of childbearing age and plan on becoming pregnant during the course of the clinical investigation.
  • Current enrollment in an investigational study evaluating another device, biologic, or drug
  • Presenting contra-indications for the devices used in the study, as indicated in the respective instruction for use (IFU)
  • Categorized as vulnerable population and requiring special treatment with respect to safeguards of well-being
  • Life expectancy less than 12 months
  • Contraindication for MRI such as use of contrast agents due to advanced renal disease, claustrophobia, implantable pacemakers, implantable cardioverter/defibrillators (ICDs),etc. (at PI discretion)
  • Presence of iron-containing metal fragments in the body
  • Unresolved pre-existing neurological deficit

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Pulsed Field Ablation: VARIPULSE Catheter with TRUPULSE Generator and VARIPULSE Pro Software

Participants undergoing cardiac ablation for management of treatment of symptomatic Persistent Atrial Fibrillation (PsAF) will undergo pulsed field ablation (PFA) with the VARIPULSE Catheter and the TRUPULSE Generator with the new VARIPULSE Pro software.

Pulsed field ablation by VARIPULSE catheter with TRUPULSE generator along with VARIPULSE Pro software will be used.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Acute Procedural Success
時間枠:Intraoperative

Acute procedural success, which is defined as electrical isolation of clinically relevant targeted PVs (confirmed by entrance block) after adenosine/isoproterenol challenge at the end of the index ablation procedure will be reported.

Intraoperative
Pulmonary Vein Isolation (PVI) Durability
時間枠:Up to 3 months post index ablation procedure

PVI durability is defined as sustained isolation of PVs that are targeted in the index ablation procedure, which is evidenced by the confirmation of isolation via the electro-anatomical mapping 90 days (+/- 14 days) post index ablation procedure.

Up to 3 months post index ablation procedure
Pulsed Field (PF) Applications Time
時間枠:Intraoperative

PF applications time will be reported.

Intraoperative
Number of PF applications
時間枠:Intraoperative

Number of PF applications will be reported.

Intraoperative
Tissue Proximity Indication (TPI)
時間枠:Intraoperative

TPI will be reported.

Intraoperative

二次結果の測定

結果測定
メジャーの説明
時間枠
Occurrence of Serious Adverse Device Effects (SADE) (Within Seven (7) days) of Index Ablation Procedure) Where the Investigational Devices were Used per Clinical Investigation Plan
時間枠:Up to 7 days post index ablation procedure

A SADE is an adverse device effect that has resulted in any of the consequences characteristic of an serious adverse event (SAE). A SAE is any event that led to any of the following: Death, Serious deterioration in the health of a participant that resulted in any of the following: life-threatening illness or injury, permanent impairment of a body structure or a body function, in-patient hospitalization or prolongation of patient hospitalization, medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to body structure or a body function, chronic disease and fetal distress, fetal death or a congenital physical or mental impairment or birth defect.

Up to 7 days post index ablation procedure
Occurrence of Unanticipated Serious Adverse Device Effects (USADEs)
時間枠:Up to 3 months post index ablation procedure

An USADE is any SAE on health, safety, any life-threatening problem, or death caused by, or associated with a device, if that effect, problem, or death was not previously identified in nature, severity, outcome, or degree of incidence in the current investigational plan or risk analysis report, or any other unanticipated serious problem associated with a device that relates to rights, safety, or welfare of participants.

Up to 3 months post index ablation procedure
Occurrence of SAEs
時間枠:At 7 days, 8 to 30 days (peri-procedural) and up to 3 months post index ablation procedure

An SAE is any event that led to any of the following: Death, Serious deterioration in the health of a participant that resulted in any of the following: life-threatening illness or injury, permanent impairment of a body structure or a body function, in-patient hospitalization or prolongation of patient hospitalization, medical or surgical intervention to prevent ife-threatening illness or injury or permanent impairment to body structure or a body function, chronic disease and fetal distress, fetal death or a congenital physical or mental impairment or birth defect.

At 7 days, 8 to 30 days (peri-procedural) and up to 3 months post index ablation procedure
Occurrence of Non-Serious Adverse Events (Non-SAEs)
時間枠:Up to 3 months post index ablation procedure

An Adverse Event (AE) means any untoward medical occurrence, unintended disease or injury or any untoward clinical signs, including an abnormal laboratory finding, in participants, users or other persons, in the context of a clinical investigation, whether or not related to the investigational device.

Up to 3 months post index ablation procedure
Occurrence of New Post-Ablation Asymptomatic and Symptomatic Cerebral Emboli Observed Post-Ablation as Determined by Magnetic Resonance Imaging (MRI) Evaluations
時間枠:Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure

Occurrence of new post-ablation asymptomatic and symptomatic cerebral emboli will be evaluated using cerebral MRI performed post-ablation.

Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure
Anatomical Location of New Post-Ablation Asymptomatic and Symptomatic Cerebral Emboli Observed Post-Ablation as Determined by MRI Evaluations
時間枠:Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure

Anatomical location of new post-ablation asymptomatic and symptomatic cerebral emboli will be evaluated using cerebral MRI performed post-ablation.

Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure
Size of New Post-Ablation Asymptomatic and Symptomatic Cerebral Emboli Observed Post-Ablation as Determined by Magnetic Resonance Imaging (MRI) Evaluations
時間枠:Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure

Size of new post-ablation asymptomatic and symptomatic cerebral emboli will be evaluated using cerebral MRI performed post-ablation.

Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure
Occurrence of New or Worsening Neurological Deficits
時間枠:Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure

Occurrence of new or worsening neurological deficits will be assessed.

Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure
Mini Mental State Examination (MMSE) Total Score
時間枠:Baseline (within 72 hours prior to ablation), and post-ablation (72 hours after ablation procedure)

The MMSE is a, structured examination of cognitive function. It has a total score of 30 points (0-30), and any score equal to or lower than 26 points indicates cognitive impairment.

Baseline (within 72 hours prior to ablation), and post-ablation (72 hours after ablation procedure)
National Institutes of Health Stroke Scale (NIHSS) Score
時間枠:Baseline (within 72 hours pre ablation procedure), and post-ablation (72 hours after ablation procedure)

The NIHSS is a clinician-reported measure of neurological deficit with scores ranging from 0 to 42. No stroke symptoms (0), mild stroke (1-4), moderate stroke (5-15), moderate to severe stroke (16-20), and sever (21-42).

Baseline (within 72 hours pre ablation procedure), and post-ablation (72 hours after ablation procedure)
Modified Rankin Scale (mRS) Scale Score
時間枠:Baseline (within 72 hours pre ablation procedure), and post-ablation (72 hours after ablation procedure)

The mRS score is a validated score measuring neurologic outcomes after cardio-pulmonary resuscitation (CPR) where:

  • mRS 0: No symptoms.
  • mRS 1: No significant disability. Able to perform all usual activities, despite some symptoms.
  • mRS 2: Slight disability. Independent but unable to perform usual activities (work, sports, leisure).
  • mRS 3. Moderate disability. Requires assistance, but able to walk alone.
  • mRS 4: Moderately severe disability. Walking assistance and/or daily living activities not possible.
  • mRS 5. Major disability. Bedridden, incontinent and requires constant nursing care and attention.
  • mRS 6: Death.
Baseline (within 72 hours pre ablation procedure), and post-ablation (72 hours after ablation procedure)
Occurrence of Severe Pulmonary Vein (PV) Stenosis
時間枠:Up to 3 months post index ablation procedure

Occurrence of severe PV stenosis as determined by Computed Tomography (CT)/ Magnetic Resonance Angiogram (MRA) evaluations will be reported.

Up to 3 months post index ablation procedure

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Biosense Webster, Inc. Clinical Trial、Biosense Webster, Inc.

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年5月19日

一次修了 (推定)

2026年12月30日

研究の完了 (推定)

2026年12月30日

試験登録日

最初に提出

2026年2月19日

QC基準を満たした最初の提出物

2026年2月19日

最初の投稿 (実際)

2026年2月23日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月3日

QC基準を満たした最後の更新が送信されました

2026年11月2日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • BWI202513
  • BWI202513 (その他の識別子:Biosense Webster, Inc.)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The data sharing policy of Johnson & Johnson MedTech is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

はい

米国で製造され、米国から輸出された製品。

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。